Nearly half of patients with advanced ovarian cancer treated with first-line poly-ADP-ribose polymerase (PARP) inhibitors experienced recurrence in this real-world study, emphasizing the need for ...

Ovarian cancer has seen a significant shift in its treatment paradigm with the introduction of poly (ADP-ribose) polymerase (PARP) inhibitors, which are now standard in the maintenance setting ...

Thanks to the scientists at the University of Oxford, this disease could be eradicated in the next few decades.

Researchers at Peter Mac have uncovered potential new heredity genes that might be responsible for causing one of the most prevalent and deadliest forms of ovarian cancer. Their work is published in ...

Nano-sized, tumor-targeting particles induced self-destruction of cancer cells in preclinical studies. A new twist on a ...

Ovarian cancer, often called the silent killer, presents one of the most serious health threats women face globally. Its ...

Scientists have made 'exciting,' patient-friendly advances in developing a non-toxic bacterial therapy, BacID, to deliver cancer-fighting drugs directly into tumors. This emerging technology holds ...

IMPACT Therapeutics has received the China National Medical Products Administration (NMPA) marketing authorisation for Senaparib capsules to treat ovarian cancer. The authorisation allows the therapy ...

Investing $350 million into research of just a few conditions could produce $14 billion in returns within women’s health, ...

High heat shock protein 60 (HSP60) expression in patients with ovarian cancer is associated with larger tumors, advanced ...